Elite Pharmaceuticals (Elite Pharmaceuticals) Change In Receivables : $-10.66 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals Change In Receivables?

Elite Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was $-5.68 Mil. It means Elite Pharmaceuticals's Accounts Receivable increased by $5.68 Mil from Sep. 2023 to Dec. 2023 .

Elite Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2023 was $-0.04 Mil. It means Elite Pharmaceuticals's Accounts Receivable increased by $0.04 Mil from Mar. 2022 to Mar. 2023 .

Elite Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was $16.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Elite Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 94.02.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Elite Pharmaceuticals's liquidation value for the three months ended in Dec. 2023 was $-3.30 Mil.

Elite Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Elite Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Change In Receivables Chart

Elite Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Receivables

Get a 7-Day Free Trial

-0.55

-2.79

0.61

0.44

-0.04

Elite Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-1.32	2.45	-3.21	-4.22	-5.68

Elite Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.66 Mil.

Elite Pharmaceuticals (OTCPK:ELTP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Elite Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	16.01	/	15.539	*	91
=	94.02

2. In Ben Graham's calculation of liquidation value, Elite Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Elite Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.816	-	28.283	+	0.75 * 16.01	+	0.5 * 14.325
=	-3.30

Elite Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Elite Pharmaceuticals (Elite Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

165 Ludlow Avenue, Northvale, NJ, USA, 07647

Website

https://www.elitepharma.com

Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Executives

Mark N Pellegrino	officer: CFO, Secretary, Treasurer	165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov	officer: Chief Commercial Officer	165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J	officer: CFO, Secretary, Treasurer	165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman	officer: CFO, Secretary, Treasurer	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer	director	C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel	director	93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc	10 percent owner	165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Plassche	officer: Executive VP of Operations	165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine	director, 10 percent owner	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye	director, 10 percent owner, officer: Chief Scientific Officer	C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc	10 percent owner	227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc	10 percent owner	227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim	director, 10 percent owner, officer: President & CEO	C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell	director	C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647